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Abstract
Objective: To assess the views and prescribing practices of doctors regarding hormone replacement
therapy (HRT).
Methods: In April 1999,103 doctors from a teaching hospital participated in a survey. Using a selfadministered questionnaire, subjects were contacted at the departments of Internal Medicine, Family
Medicine, Obstetrics and Gynaecology, and Orthopaedics.
Results: Seventy-two percent were below 40 years of age and 67% of the respondents were male. Most
doctors believed that HRT decreases the risk of subsequent osteoporosis (97%), ischaemic heart disease
(77%) and depression associated with menopause (64%). Doctors generally considered menopausal
symptoms (90%), premature menopause (87%), surgical menopause (85%) and osteoporotic fracture
(77%) as clear indications for hormone replacement therapy. Absolute contraindications to the therapy
were stated as recent breast cancer (82%) and recent endometrial cancer (84%). Among the specialties
covered, there were differing views on proposed duration of HRT. It was generally believed that a
pelvic examination, cervical smear and mammography were pre-requisites when initiating and
monitoring HRT. Majority (69%) felt that HRT should be offered to all menopausal women, assuming
no contraindications and most (73%) did discuss HRT with their patients. However, less than 10% of
the menopausal patients under their care were using HRT. Those doctors not in favor of universal
offering of HRT (31%) considered unreliable patient folio w up to be the main reason. Females were
two times more likely to discuss HRT with their patients (p= .08). Doctors who discussed HRT with
their patients were four times more likely to consider HRT for themselves or their spouses (p= .13).
Gynecologists were eight times more likely to prescribe HRT than non-gynecologists (p= .001).
Conclusion: Doctors are positively disposed to the universal offering, and use of HRT. Further studies
are needed to understand a possible gap between perceived and actual prescribing practice (JPMA
51:450,2001).
Introduction
Hormone Replacement Therapy (HRT) consists of treatment with estrogen or a combination of
estrogen plus progestin. There is extensive data suggesting that HRT is effective in alleviating the
effects of the menopause and in protecting against the chronic cardiovascular and cerebrovascular
consequences of estrogen deficiency1-4. The consensus amongst specialists is that contraindications to
HRT are few and less than those associated with oral contraceptives5. The American College of
Physicians recommends that all women, regardless of race, should consider HRT6. Despite this fact, the
current use of HRT is still low. An international survey indicated current rate of use of HRT in women
aged 40-69 to be 7% in UK7 and 9% in Scotland8, 30% in USA, 21% in Sweden and 25% in France9.
According to Ringa10 the difference between the prevalence of climacteric complaints and HRT use
rates may be attributed to unwillingness on the part of women to use HRT, or the part of physicians to
prescribe it. HRT use is strongly related to interactions with the physicians; women are likely to use
written materials as a source of information in making decisions about HRT, and most women feel that

the amount of information received about HRT is inadequate”. A recommendation by a doctor is one of
the major factors determining compliance with subsequent prescription for HRT. About 75% of nonusers of HRT would consider HRT if so recommended by their doctor. The doctor’s attitude was found
to be a factor in encouraging compliance12.
Bryce and Lilford13 found that the approach of general practitioners (GP) to prescribing HRT was
guarded with regard to both frequency and duration. The study carried out by Wilkes and Meade14
showed that there was considerable doubt among GPs as to the balance between the beneficial and
harmful effects of HRT in the long term. However, other studies found that the GPs surveyed were
generally able to recognize the menopause by its complaints and that they had a positive attitude
towards treatment , but many were skeptical of its chronic use and use in women with cardiovascular
conditions15,16 Doctors differed in opinion as to who should initiate therapy, gynecologists or GPs.
However, the studies concerned were conducted in developed countries and the situation could be
different in Pakistan. This study reports the views of doctors about prescribing HRT in a tertiary care
hospital.
Methods
This cross-sectional survey, was conducted in April 1999 at The Aga Khan University Hospital
(AKUH), Karachi. As a convenient sample, we chose the doctors working at AKUH in the departments
of internal medicine, gynecology, orthopedics, and family medicine, A self-administered questionnaire
was distributed amongst 125 doctors (consultants, residents, and medical officers), who were present in
their departments. units or wards .The questionnaire was pre-tested on 15 doctors.
EPI-INFO 6 was used to calculate sample size. With a confidence interval of 95%, a power of 80 and a
positive attitude of at least 40% towards HRT, we estimated the sample size to be 96.
Data was coded before entry and it was analyzed using EPI INFO 6 statistical program software. Odds
ratio was used as a measure of association. Levels of significance used were confidence interval of
95%.
Results
Of the 125 questionnaires, 103 were returned completed, making a response rate of 82%.

Figure shows The majority of responders (72%) were below 40 years of age and 67% responders were
male. Most doctors believed that HRT decreases the risk of osteoporosis (97%), ischemic heart disease
(77%) and depression (64%) subsequent to menopause. 62% felt that the use of HRT does not decrease
the risk of hypertension. Regarding prevention of cerebrovascular accident (CVA), 32% felt that HRT
decreased the risk, 44% disagreed, and 18% did not know.
Doctors generally considered menopausal symptoms. premature menopause, surgical menopause, and
osteoporotic fracture as clear indications for hormone replacement therapy. (Table 1).

Regarding contraindications to HRT, the majority considered recent breast cancer (82%) and recent
endometrial cancer (84%) as absolute contraindications. More than half of the respondents (54%)
considered a family history of breast cancer to be a relative contraindication. Fifty nine percent
respondents felt that HRT should be given for more than 10 years. Almost half of the gynecologists
(54%) felt that HRT should be prescribed indefinitely. In orthopedics, a shorter duration was preferred,
that is. 55% believed in URT for less than five years.

Table 2 shows the investigations that doctors considered necessary before starting HRT. It was
generally believed that a pelvic examination, cervical smear and mammography were specifically
indicated when initiating and monitoring HRT. Breast examination and measurement of blood pressure
were also considered necessary for monitoring HRT. Thirty-five percent of the respondents felt
comfortable prescribing HRT themselves whereas the rest (61 .2%) referred to gynecologists.
Gynecologists were found to be 8 times more likely to prescribe HRT then non-gynecologists (Odds
ratio (OR) 8.5; 95% Cl: 1.93 - 43.98). The majority of family medicine practitioners felt at ease while
prescribing HRT (67%). Among other specialties, the general trend was to refer.
Among non-Gynecologists, doctors in family medicine were 15 times more likely to prescribe HRT, as
compared to cardiologists, orthopedic surgeons, and internists. (OR=15; 95%Cl: 4.41 - 55.9).
Only 32% of doctors had patients on HR’T, however, these patients comprised less than 10% of the
menopausal patients under their care. 14% of doctors did not respond, 25% did not know and 18% of
doctors had no patients on HRT.
The majority of the doctors (69%) favored universal offering of HRT assuming no contraindications
and most doctors (73%) did discuss HRT with their patients.
Majority of gynaecologists (100%) and family practitioners (90%) discussed HRT with their patients,
whereas only 54% of internists did so.
Those doctors who were not in favor of universal offering of HRT (31%), considered the following to
be their main reasons: unreliable patient follow up, risks of HRT outweigh it’s benefits, unwilling
patients and the need for further research on the subject. Lack of availability of HRT, a time consuming
screening process, that HRT interfered with a natural phenomenon and that it is not a priority for a
developing country were not considered to be important reasons.
Female doctors were two times more likely to discuss HRT with their patients, as compared to male

doctors. People who discussed HRT with their patients were 4 times more likely to consider HRT for
themselves or their spouses. Current medical literature was the primary source for 71% of the doctors.
Discussion
This study indicated that the doctors at this hospital are fairly aware and positively disposed towards
HRT. There was possibly a disproportionate response from young doctors, who might be more
positively inclined to HRT than their older colleagues.
The doctors are positively disposed to HRT, regarding its role in ischemic heart disease, osteoporosis,
depression and treatment of menopausal symptoms, premature menopause and surgical menopause.
Reservations exist over the role of HRT in the prophylaxis of cerebrovascular accident and
Hypertension. While estrogen therapy has little control on blood pressure there is data that it can reduce
significantly mortality of ischemic heart disease2. Data indicating a relative risk of 0.53 of death from
stroke following estrogen therapy3 differ with more recent data17, which show no reduction (or
increase) in risk of stroke. The bulk of evidence now suggests that in contrast to the combined oral
contraceptive, HRT does not cause or aggravate essential hypertension18,19. However, 23% of the
doctors in our study, considered even treated hypertension to be an absolute or relative contraindication
to HRT.
An over guarded approach, or investigations and monitoring that are too invasive and expensive may
daunt women from opting for HRT. There is no evidence to link cervical abnormality to HRT16 but the
majority of the doctors’ required cervical smears before HRT. Regarding duration of therapy, the
maximum benefits of therapy in reducing risk for coronary heart disease and osteoporotic fractures are
more likely to be achieved with long-term therapy (10 to 20 years or more). 40% of the respondents in
this study felt that HRT should be given for less then 10 years. Family practitioners and gynecologists
were comfortable with prescribing HRT, while in other specialties the trend was to refer.
Most of the doctors favored universal offering of HRT and almost all of them thought that every
women should be educated about HRT. Unreliable patient follow up, unwillingness on the part of the
patients and likely risks versus benefits were cited as important reasons for not offering HRT. Financial
cost, cost in time for supervision and monitoring and concern about the pharmacological approach to
what is seen as a natural process in humans were not considered important reasons for not offering
HRT as opposed to other studies13.
On the basis of the results of this study, one might get the notion that there was no major reluctance on
the part of the doctors to use HRT. However, less than 10% of the menopausal patients under their care
were using HRT. A possible justification is that the unwillingness to use HRT may come primarily from
the women in our setting. Whether or not women really are hesitant to use HRT would require further
investigation.
We recommend that guidelines in keeping with the most recent literature should be formulated and
made available to all doctors. Furthermore, seminars and workshops should be held to highlight the
preventive role of HRT during and after the climacteric phase of life.
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